Real-world Outcomes of Adalimumab in Hidradenitis Suppurativa: A 10-year Retrospective Longitudinal Study

Q: What does this research mean for the field?

Adalimumab demonstrates sustained long-term real-world effectiveness in patients with moderate-to-severe hidradenitis suppurativa, with high rates of clinical response maintained up to one year and beyond. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Patrícia Moreira Gomes; Rúben Costa; Bárbara Vieira Granja; Filomena Azevedo; Cármen Lisboa

doi:10.2340/actadv.v106.adv-2026-0636

July 1, 2026Acta Dermato VenereologicaOpen Access

Real-world Outcomes of Adalimumab in Hidradenitis Suppurativa: A 10-year Retrospective Longitudinal Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to evaluate the long-term effectiveness of adalimumab in treating hidradenitis suppurativa.
Conducted a retrospective longitudinal study of 79 patients treated with adalimumab from 2015 to 2024.
Assessed disease severity using the Hurley staging system and treatment response using HiSCR50 criteria.
Monitored HS activity and response at baseline, Week 16, Week 24, and Week 52.
At Week 16, 91.3% of patients achieved HiSCR50, increasing to 92.8% at Week 24.
85.1% of patients maintained HiSCR50 response at Week 52 after initial success.
Among 34 patients followed for over a year, 64.7% sustained HiSCR50 response up to 114 months.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Retrospective study shows long-term response to adalimumab in hidradenitis suppurativa, indicating its continued relevance for treatment decisions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gomes et al. (2026) studied this question.

synapsesocial.com/papers/6a48a30989561a0c2d78d3e1 https://doi.org/10.2340/actadv.v106.adv-2026-0636

View Full Paper

Ask AI

Bookmark

Share

Real-world Outcomes of Adalimumab in Hidradenitis Suppurativa: A 10-year Retrospective Longitudinal Study

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Real-world Outcomes of Adalimumab in Hidradenitis Suppurativa: A 10-year Retrospective Longitudinal Study

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading